Global Parkinson’s Disease Therapeutics Market Strategic Research Report (2025–2036)
Western Market Research predicts that the Global Parkinson’s Disease Therapeutics Market was valued at USD 6.85 Billion in 2025 and is expected to reach USD 13.52 Billion by the year 2036, growing at a CAGR of 6.4% globally during the forecast period.
1. Global Parkinson’s Disease Therapeutics Market Overview
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder globally, characterized by the progressive loss of dopaminergic neurons. The market is currently undergoing a paradigm shift from traditional symptomatic relief (Levodopa-centric) to advanced delivery systems and disease-modifying therapies (DMTs).
The research study evaluates the intricate balance between pharmacological interventions and surgical/device-based therapies. By analyzing data from 2020–2024, this report identifies critical patterns in patient adherence, the rising importance of treating non-motor symptoms (anxiety, sleep disorders, cognitive decline), and the rapid integration of wearable technology for real-time disease monitoring.
2. Impact of COVID-19 on Parkinson’s Disease Therapeutics Market
The pandemic initially challenged PD management due to the vulnerability of the elderly demographic and the interruption of physical therapy sessions. However, it acted as a primary catalyst for Tele-Neurology. The market saw a permanent shift in how Parkinson’s is managed, with a surge in the use of remote monitoring devices and "smart" infusion pumps. Post-pandemic, the R&D focus has intensified toward understanding the long-term neurological impacts of viral infections, sustaining high investment in the neuro-therapeutics sector.
3. Market Segmentation
By Therapeutics Type:
-
Medications:
-
Dopamine Precursors (Levodopa/Carbidopa)
-
Dopamine Agonists (Pramipexole, Ropinirole)
-
MAO-B Inhibitors (Selegiline, Rasagiline)
-
COMT Inhibitors (Entacapone, Opicapone)
-
Anticholinergics & Adenosine A2A Receptor Antagonists
-
-
Medical Devices:
-
Deep Brain Stimulation (DBS) Systems
-
Levodopa-Carbidopa Intestinal Gel (LCIG) Infusion Pumps
-
Wearable Sensors for Kinetic Monitoring
-
By Route of Administration (New Segment):
-
Oral: Tablets and extended-release capsules.
-
Transdermal: Patches for continuous drug delivery (Rotigotine).
-
Subcutaneous/Infusion: Constant delivery to minimize "off" periods.
-
Inhalation: Rescue therapies for sudden "off" episodes.
By Application (Patient Age Group):
-
Under 40 Years Old: Focused on long-term dopamine-sparing strategies.
-
40-65 Years Old: The core demographic for early-to-mid stage management.
-
Above 65 Years Old: Largest segment; focused on polypharmacy management and advanced device intervention.
By Distribution Channel (New Segment):
-
Hospital Pharmacies: Central for DBS and pump-based initiations.
-
Retail Pharmacies: Primary source for daily maintenance medication.
-
Online Pharmacies: Growing segment for recurring chronic prescriptions.
4. Competitive Landscape: Top Key Players
The market features a blend of diversified pharmaceutical giants and specialized MedTech innovators.
-
AbbVie (USA) – Market leader in advanced delivery (Duopa).
-
Teva Pharmaceutical (Israel)
-
Novartis AG (Switzerland)
-
GlaxoSmithKline (GSK) (UK)
-
Boehringer Ingelheim (Germany)
-
Merck & Co. (USA)
-
Roche (F. Hoffmann-La Roche) (Switzerland)
-
Kyowa Kirin (Japan)
-
Lundbeck (Denmark)
-
Ucb Pharma (Belgium)
-
Neurocrine Biosciences (USA)
-
Amneal Pharmaceuticals (USA)
-
Acadia Pharmaceuticals (USA) – Focus on PD Psychosis.
-
Medtronic (Ireland) – Leader in DBS Technology.
-
Boston Scientific (USA)
-
Abbott Laboratories (USA)
-
Sunovion Pharmaceuticals (USA)
-
Bausch Health (Canada)
-
Zambon (Italy)
5. Regional Analysis
-
North America: Holds the largest share (~40%) due to high diagnostic rates, premium pricing for new biologics/devices, and a robust clinical trial ecosystem.
-
Europe: Driven by advanced healthcare systems in Germany, France, and the UK, with high adoption of Deep Brain Stimulation (DBS).
-
Asia-Pacific: The fastest-growing region. Aging populations in Japan and China, coupled with improving healthcare access in India, are driving massive volume growth.
-
South America: Brazil and Argentina are emerging as key markets for generic levodopa and specialty agonists.
-
Middle East & Africa: Growth is centered in the GCC countries through investments in specialized neuro-rehabilitation centers.
6. Porter’s Five Forces Analysis
-
Threat of New Entrants (Low): High R&D barriers, complex clinical trial requirements for neuro-drugs, and established patent protection for devices like DBS.
-
Bargaining Power of Buyers (Medium-High): Large insurance payers and government health bodies exert pressure on the pricing of advanced biologics and devices.
-
Bargaining Power of Suppliers (Low): Standard chemical precursors are widely available; specialized microchips for DBS have moderate supplier leverage.
-
Threat of Substitutes (Low): While physical therapy and exercise are vital, they cannot replace pharmacological or surgical intervention.
-
Competitive Rivalry (High): Major players are aggressively competing to solve the "Off-time" challenge and improve drug delivery consistency.
7. SWOT Analysis
-
Strengths: Inelastic demand due to chronic nature; high unmet need for DMTs; technological synergy between drugs and devices.
-
Weaknesses: High cost of advanced therapies; side effects (Dyskinesia) of long-term Levodopa use.
-
Opportunities: Gene and Cell Therapy (Dopamine-producing cell transplants); AI-driven early diagnosis through gait analysis.
-
Threats: Patent expirations for major COMT/MAO-B inhibitors; strict regulatory hurdles for stem-cell-based treatments.
8. Trend Analysis
-
Continuous Dopaminergic Stimulation (CDS): A shift toward pumps and patches that prevent the "peaks and valleys" of oral dosing.
-
Targeting Alpha-Synuclein: R&D focus is moving from dopamine replacement to clearing toxic protein aggregates.
-
Wearable Integration: Devices that track tremors and bradykinesia to help doctors adjust medication dosages remotely.
9. Drivers & Challenges
-
Drivers:
-
The "Silver Tsunami": Rapidly aging global population.
-
Innovations in "Rescue" therapies for sudden motor fluctuations.
-
Rising awareness and de-stigmatization of neurological disorders.
-
-
Challenges:
-
The Blood-Brain Barrier (BBB) remains a significant hurdle for drug delivery.
-
High cost and surgical risks associated with DBS systems.
-
10. Value Chain Analysis
-
Drug/Device Discovery: High-investment phase focusing on neuro-protection.
-
Clinical Validation: Extensive Phase I-III trials focused on "On/Off" time reduction.
-
Manufacturing: High-precision production of hardware (DBS) and stable chemical formulations.
-
Specialized Distribution: Cold-chain requirements for certain biologics.
-
Neurology Consultation: Expert diagnosis and personalized titration.
-
End-Patient Adherence: Ongoing monitoring and caregiver support.
11. Quick Recommendations for Stakeholders
-
For Manufacturers: Invest in non-invasive delivery systems (inhalation or high-tech patches) to capture the market segment averse to surgery or frequent injections.
-
For Investors: Focus on companies in the Alpha-Synuclein antibody pipeline, as disease-modifying therapies represent the highest long-term valuation potential.
-
For Healthcare Providers: Implement integrated care models that combine neurology with geriatric psychiatry and specialized physical therapy.
-
For Payers: Adopt Value-Based Reimbursement models for DBS systems, tied to long-term reductions in secondary care and medication costs.
1. Market Overview of Parkinson's Disease Therapeutics
1.1 Parkinson's Disease Therapeutics Market Overview
1.1.1 Parkinson's Disease Therapeutics Product Scope
1.1.2 Market Status and Outlook
1.2 Parkinson's Disease Therapeutics Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Parkinson's Disease Therapeutics Historic Market Size by Regions
1.4 Parkinson's Disease Therapeutics Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Parkinson's Disease Therapeutics Sales Market by Type
2.1 Global Parkinson's Disease Therapeutics Historic Market Size by Type
2.2 Global Parkinson's Disease Therapeutics Forecasted Market Size by Type
2.3 Medications Therapeutics
2.4 Medical Devices Therapeutics
3. Covid-19 Impact Parkinson's Disease Therapeutics Sales Market by Application
3.1 Global Parkinson's Disease Therapeutics Historic Market Size by Application
3.2 Global Parkinson's Disease Therapeutics Forecasted Market Size by Application
3.3 Under 40 Years Old
3.4 40-65 Years Old
3.5 Above 65 Years Old
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Parkinson's Disease Therapeutics Production Capacity Market Share by Manufacturers
4.2 Global Parkinson's Disease Therapeutics Revenue Market Share by Manufacturers
4.3 Global Parkinson's Disease Therapeutics Average Price by Manufacturers
5. Company Profiles and Key Figures in Parkinson's Disease Therapeutics Business
5.1 GSK
5.1.1 GSK Company Profile
5.1.2 GSK Parkinson's Disease Therapeutics Product Specification
5.1.3 GSK Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.2 Novartis
5.2.1 Novartis Company Profile
5.2.2 Novartis Parkinson's Disease Therapeutics Product Specification
5.2.3 Novartis Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.3 Boehringer Ingelheim
5.3.1 Boehringer Ingelheim Company Profile
5.3.2 Boehringer Ingelheim Parkinson's Disease Therapeutics Product Specification
5.3.3 Boehringer Ingelheim Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.4 Teva Pharmaceutical
5.4.1 Teva Pharmaceutical Company Profile
5.4.2 Teva Pharmaceutical Parkinson's Disease Therapeutics Product Specification
5.4.3 Teva Pharmaceutical Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.5 Abbvie
5.5.1 Abbvie Company Profile
5.5.2 Abbvie Parkinson's Disease Therapeutics Product Specification
5.5.3 Abbvie Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.6 Merck
5.6.1 Merck Company Profile
5.6.2 Merck Parkinson's Disease Therapeutics Product Specification
5.6.3 Merck Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.7 Akorn
5.7.1 Akorn Company Profile
5.7.2 Akorn Parkinson's Disease Therapeutics Product Specification
5.7.3 Akorn Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.8 Kyowa Hakko Kirin Pharma
5.8.1 Kyowa Hakko Kirin Pharma Company Profile
5.8.2 Kyowa Hakko Kirin Pharma Parkinson's Disease Therapeutics Product Specification
5.8.3 Kyowa Hakko Kirin Pharma Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.9 Astellas Pharma
5.9.1 Astellas Pharma Company Profile
5.9.2 Astellas Pharma Parkinson's Disease Therapeutics Product Specification
5.9.3 Astellas Pharma Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.10 Desitin Arzneimittel
5.10.1 Desitin Arzneimittel Company Profile
5.10.2 Desitin Arzneimittel Parkinson's Disease Therapeutics Product Specification
5.10.3 Desitin Arzneimittel Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.11 Endo Pharmaceuticals
5.11.1 Endo Pharmaceuticals Company Profile
5.11.2 Endo Pharmaceuticals Parkinson's Disease Therapeutics Product Specification
5.11.3 Endo Pharmaceuticals Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.12 F.Hoffmann-La Roche
5.12.1 F.Hoffmann-La Roche Company Profile
5.12.2 F.Hoffmann-La Roche Parkinson's Disease Therapeutics Product Specification
5.12.3 F.Hoffmann-La Roche Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.13 H.Lundbeck
5.13.1 H.Lundbeck Company Profile
5.13.2 H.Lundbeck Parkinson's Disease Therapeutics Product Specification
5.13.3 H.Lundbeck Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.14 Valeant
5.14.1 Valeant Company Profile
5.14.2 Valeant Parkinson's Disease Therapeutics Product Specification
5.14.3 Valeant Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.15 Apokyn
5.15.1 Apokyn Company Profile
5.15.2 Apokyn Parkinson's Disease Therapeutics Product Specification
5.15.3 Apokyn Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.16 Orion
5.16.1 Orion Company Profile
5.16.2 Orion Parkinson's Disease Therapeutics Product Specification
5.16.3 Orion Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.17 Stada Arzneimittel
5.17.1 Stada Arzneimittel Company Profile
5.17.2 Stada Arzneimittel Parkinson's Disease Therapeutics Product Specification
5.17.3 Stada Arzneimittel Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.18 US WorldMeds
5.18.1 US WorldMeds Company Profile
5.18.2 US WorldMeds Parkinson's Disease Therapeutics Product Specification
5.18.3 US WorldMeds Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
5.19 Bausch Health
5.19.1 Bausch Health Company Profile
5.19.2 Bausch Health Parkinson's Disease Therapeutics Product Specification
5.19.3 Bausch Health Parkinson's Disease Therapeutics Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Parkinson's Disease Therapeutics Market Size
6.2 North America Parkinson's Disease Therapeutics Key Players in North America
6.3 North America Parkinson's Disease Therapeutics Market Size by Type
6.4 North America Parkinson's Disease Therapeutics Market Size by Application
7. East Asia
7.1 East Asia Parkinson's Disease Therapeutics Market Size
7.2 East Asia Parkinson's Disease Therapeutics Key Players in North America
7.3 East Asia Parkinson's Disease Therapeutics Market Size by Type
7.4 East Asia Parkinson's Disease Therapeutics Market Size by Application
8. Europe
8.1 Europe Parkinson's Disease Therapeutics Market Size
8.2 Europe Parkinson's Disease Therapeutics Key Players in North America
8.3 Europe Parkinson's Disease Therapeutics Market Size by Type
8.4 Europe Parkinson's Disease Therapeutics Market Size by Application
9. South Asia
9.1 South Asia Parkinson's Disease Therapeutics Market Size
9.2 South Asia Parkinson's Disease Therapeutics Key Players in North America
9.3 South Asia Parkinson's Disease Therapeutics Market Size by Type
9.4 South Asia Parkinson's Disease Therapeutics Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Parkinson's Disease Therapeutics Market Size
10.2 Southeast Asia Parkinson's Disease Therapeutics Key Players in North America
10.3 Southeast Asia Parkinson's Disease Therapeutics Market Size by Type
10.4 Southeast Asia Parkinson's Disease Therapeutics Market Size by Application
11. Middle East
11.1 Middle East Parkinson's Disease Therapeutics Market Size
11.2 Middle East Parkinson's Disease Therapeutics Key Players in North America
11.3 Middle East Parkinson's Disease Therapeutics Market Size by Type
11.4 Middle East Parkinson's Disease Therapeutics Market Size by Application
12. Africa
12.1 Africa Parkinson's Disease Therapeutics Market Size
12.2 Africa Parkinson's Disease Therapeutics Key Players in North America
12.3 Africa Parkinson's Disease Therapeutics Market Size by Type
12.4 Africa Parkinson's Disease Therapeutics Market Size by Application
13. Oceania
13.1 Oceania Parkinson's Disease Therapeutics Market Size
13.2 Oceania Parkinson's Disease Therapeutics Key Players in North America
13.3 Oceania Parkinson's Disease Therapeutics Market Size by Type
13.4 Oceania Parkinson's Disease Therapeutics Market Size by Application
14. South America
14.1 South America Parkinson's Disease Therapeutics Market Size
14.2 South America Parkinson's Disease Therapeutics Key Players in North America
14.3 South America Parkinson's Disease Therapeutics Market Size by Type
14.4 South America Parkinson's Disease Therapeutics Market Size by Application
15. Rest of the World
15.1 Rest of the World Parkinson's Disease Therapeutics Market Size
15.2 Rest of the World Parkinson's Disease Therapeutics Key Players in North America
15.3 Rest of the World Parkinson's Disease Therapeutics Market Size by Type
15.4 Rest of the World Parkinson's Disease Therapeutics Market Size by Application
16 Parkinson's Disease Therapeutics Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Market Segmentation
By Therapeutics Type:
-
Medications:
-
Dopamine Precursors (Levodopa/Carbidopa)
-
Dopamine Agonists (Pramipexole, Ropinirole)
-
MAO-B Inhibitors (Selegiline, Rasagiline)
-
COMT Inhibitors (Entacapone, Opicapone)
-
Anticholinergics & Adenosine A2A Receptor Antagonists
-
-
Medical Devices:
-
Deep Brain Stimulation (DBS) Systems
-
Levodopa-Carbidopa Intestinal Gel (LCIG) Infusion Pumps
-
Wearable Sensors for Kinetic Monitoring
-
By Route of Administration (New Segment):
-
Oral: Tablets and extended-release capsules.
-
Transdermal: Patches for continuous drug delivery (Rotigotine).
-
Subcutaneous/Infusion: Constant delivery to minimize "off" periods.
-
Inhalation: Rescue therapies for sudden "off" episodes.
By Application (Patient Age Group):
-
Under 40 Years Old: Focused on long-term dopamine-sparing strategies.
-
40-65 Years Old: The core demographic for early-to-mid stage management.
-
Above 65 Years Old: Largest segment; focused on polypharmacy management and advanced device intervention.
By Distribution Channel (New Segment):
-
Hospital Pharmacies: Central for DBS and pump-based initiations.
-
Retail Pharmacies: Primary source for daily maintenance medication.
-
Online Pharmacies: Growing segment for recurring chronic prescriptions.
